Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Tiago Girao
AddedFeb 19, 2024
UpdatedMay 31, 2026
Tiago Girao

Tiago Girao

Board Member, Landos Biopharma

CrunchbaseLinkedIn

Tiago Girao's Career

Landos Biopharma
Landos Biopharma

Blacksburg, VA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Tiago Girao's Career

Landos Biopharma
Landos Biopharma
Public$70M372017Blacksburg, VA, US
Board Member· Board

Leadership at Landos Biopharma

Josep Bassaganya-RieraJosep Bassaganya-RieraBoard Member
Chris GarabedianChris GarabedianBoard Member
Roger AdsettRoger AdsettBoard Member
Tim MaylebenTim MaylebenBoard Member
Gregory OakesGregory OakesBoard Member

Similar to Landos Biopharma

Lapix TherapeuticsLapix TherapeuticsBoston, MA, USDrugs, Therapeuticsest. 2020Lapix TherapeuticsBoston, MA, US · est. 2020

Lapix Therapeutics: Enhancing immune response and drug safety through targeted therapeutic modulation.

Series A · $5.9M9
Lumos PharmaLumos PharmaAustin, TX, USPharmaceuticals, Therapeuticsest. 1999Lumos PharmaAustin, TX, US · est. 1999

Lumos Pharma: A global biopharmaceutical firm based in Austin, US, specializing in rare disease therapeutics.

Public · $53.5M29
Palisade BioPalisade BioCarlsbad, CA, USTherapeuticsest. 2001Palisade BioCarlsbad, CA, US · est. 2001

Palisade Bio, Inc.: A global biopharmaceutical firm innovating therapies for gastrointestinal complications.

Public · $55.4M12
Bond BiosciencesBond BiosciencesNew York City, NY, USPharmaceuticals, Therapeuticsest. 2016Bond BiosciencesNew York City, NY, US · est. 2016

Bond Biosciences: A private biopharma firm developing non-absorbed oral therapeutics for human diseases.

Series B · $11.8M7

Tiago Girao's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Tiago Girao

Alexander K. ArrowAlexander K. ArrowBoard Member · Paragonix TechnologiesTim CabralTim CabralBoard Member · ServiceTitanTodd ShegogTodd ShegogBoard Member · Cogent BiosciencesGary AtkinsonGary AtkinsonBoard Member · Zylo TherapeuticsBrian Di DonatoBrian Di DonatoBoard Member · IecureRobert HuginRobert HuginBoard Member · Celgene